CORRECTING and REPLACING Dr. Rajesh Shrotriya, Chairman, President and CEO of Spectrum Pharmaceuticals Talks to the Wall Street Transcript.Business Editors CORRECTION...by The Wall Street Transcript NEW YORK--(BUSINESS WIRE)--March 11, 2004 In BW5568 issued March 11, 2004: The Source of release should read: The Wall Street Transcript (sted: Spectrum Pharmaceuticals, Inc.). The corrected release reads: DR. RAJESH SHROTRIYA, CHAIRMAN, PRESIDENT AND CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. OF SPECTRUM PHARMACEUTICALS TALKS TO THE WALL STREET TRANSCRIPT The Wall Street Transcript has published an in-depth interview with Dr. Rajesh Shrotriya, Chairman, President and CEO of Spectrum Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :SPPI SPPI Sprague's Pipit (bird species Anthus spragueii ) SPPI Stormin Protection Products Inc. SPPI Structure of Policy Provisioning Information ) in which he talks at length about the Company. The entire 2,500 word interview is available free online at http://www.twst.com/ceos.htm Spectrum Pharmaceuticals' primary focus is to develop in-licensed drug candidates for the treatment and supportive care supportive care, n medical and other interventions that attempt to support and make comfortable rather than to cure. of cancer patients. The Company is actively working to develop, seek approval for and oversee the marketing of generic drugs in the U.S. In describing the Company's current strategy Dr. Shrotriya states "Our generic strategy is intended to leverage our manufacturing and marketing partner infrastructure to generate revenue and profits which we then can use to fund the development of our proprietary oncology pipeline." Regarding the current drug pipeline Dr. Shrotriya states "We have three drug candidates in late-stage clinical trials for three deadly diseases. The first drug candidate, satraplatin, is for hormone refractory prostate cancer prostate cancer, cancer originating in the prostate gland. Prostate cancer is the leading malignancy in men in the United States and is second only to lung cancer as a cause of cancer death in men. , and is in a Phase III clinical trial Noun 1. phase III clinical trial - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the being conducted by our co-development partner, GPC Biotech AG. The second is a drug called EOquin, and is in Phase II trials for refractory superficial bladder cancer bladder cancer Malignant tumour of the bladder. The most significant risk factor associated with bladder cancer is smoking. Exposure to chemicals called arylamines, which are used in the leather, rubber, printing, and textiles industries, is another risk factor. . The third is a drug called Elsamitrucin, and is in Phase II trials for refractory non-Hodgkin's lymphoma." The Wall Street Transcript does not endorse the views of any interviewees nor does it make stock recommendations. For subscription information call 800/246-7673. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion